other uses Taxobox status name Lynx ref name msw3 MSW3 Wozencraft pages 541 542 ref image Lynxlynx poing.jpg image caption Eurasian lynxLynxlynx regnum Animal ia phylum Chordate Chordata classis Mammal ia ordo Carnivora familia Felidae subfamilia Felinae genus Lynx genus authority Robert Kerr writer Kerr , 1792 type species Eurasian LynxLynxlynx type species authority Carolus Linnaeus Linnaeus , 1758 subdivision ranks Species subdivision Lynxlynx br Lynx canadensis br Lynx pardinus br Lynx rufus range map Lynx range.png range map caption Lynx ranges A lynx IPAc en icon l k s ref name OxfordDic cite web title Definition of lynx from Oxford Dictionary work Oxford Dictionary url http ... plural lynx or lynxes ref name Longman cite web title lynx Definition from Longman English Dictionary Online work Longman Dictionary url http www.ldoceonline.com dictionary lynx accessdate October 5, 2010 ref is any of the four Lynx genus species of medium sized wildcats. The name lynx originated ... root leuk , meaning light, brightness , ref name ConstelOfWords cite web title Lynx url http www.constellationsofwords.com ... of the genus Felis . Neither the caracal , sometimes called the Persian lynx or African lynx, nor the jungle cat , called the swamp lynx, is a member of the Lynx genus. Appearance Image Lynx lynx2.jpg thumb left The Eurasian lynxLynxlynxLynx have short tails and characteristic tufts of black hair ... with dark brown spots, especially on the limbs. All species of lynx also have white fur on their chests ..., the lynx s colouring, fur height and paw size varies by its climate range in the Southwestern United States , the fur and colour are short haired, dark and the paws are smaller and less padded as the lynx ... lynx , while the largest is the Eurasian lynx , with considerable variations within species. br style clear both class wikitable Physical characteristics of Lynx species Species Weight Length Height standing at shoulders ROWSPAN 2 Eurasian lynx males convert 18 to 30 kg lb ROWSPAN 2 ... more details
Durata Therapeutics , established in 2009, is a clinical development stage pharmaceutical company. Durata focuses on new therapeutics to treat infectious diseases . Durata has several projects in its pipeline, most notably the antibacterial, dalbavancin . The company acquired this long acting semisynthetic lipoglycopeptide antibiotic from Pfizer in December 2009. ref http www.genengnews.com gen news highlights durata therapeutics acquires pfizer s subsidiary that develops antibiotics 71646582 Durata Therapeutics Acquires Pfizer s Subsidiary that Develops Antibiotics. GEN News Highlights Dec 21, 2009. ref Durata has since initiated two Phase III studies of dalbavancin for intravenous IV treatment of acute bacterial skin and skin structure infections. ref http www.dddmag.com news Durata Begins Dalbavancin Study Enrollment 10511.aspx Durata Begins Dalbavancin Study Enrollment. Drug Discovery & Development October 05, 2011. ref In March 2012, Durata filed with the SEC to raise up to 86 million in an initial public offering. ref cite news url http www.renaissancecapital.com ipohome news Biotech Durata Therapeutics files for 86 million US IPO 11322.html title Biotech Durata Therapeutics files for 86 million US IPO work Renaissance Capital US company Renaissance Capital date 22 March 2012 ref References reflist External links http www.duratatherapeutics.com Durata Therapeutics corporate website Portal Companies Pharmaceutical companies of the United States company stub DEFAULTSORT Durata Therapeutics Category Pharmaceutical companies of the United States ... more details
Italic title infobox journal title Pharmacology & Therapeutics cover File PharmacologyandTherapueticsFrontCover.gif abbreviation Pharmacol. Ther. discipline Pharmacology frequency Monthly history 1976 present publisher Elsevier editor S.J. Enna ISSN 0163 7258 eISSN 1879 016X CODEN PHTHDT OCLC 04981366 website http www.elsevier.com wps find journaldescription.cws home 525486 description description link1 http sciencedirect.com science journal 01637258 link1 name Online access impact 8.694 impact year 2010 openaccess optional Pharmacology & Therapeutics is a medical journal medical review journal published by Elsevier . It incorporates Pharmacology & Therapeutics. Part A Chemotherapy, Toxicology and Metabolic Inhibitors and Pharmacology & Therapeutics. Part B General and Systematic Pharmacology , both originally published by Oxford University Press . External links Official http www.elsevier.com wps find journaldescription.cws home 525486 description description med journal stub Category Pharmacology journals Category Elsevier academic journals Category Publications established in 1976 Category English language journals Category Monthly journals fr Pharmacology & Therapeutics ... more details
Orphan date January 2012 Infobox Company company name Silence Therapeutics PLC company type Public LSE SLN foundation 1994 industry Pharmaceutical company Pharmaceuticals num employees 50 homepage http www.silence therapeutics.com www.silence therapeutics.com Silence Therapeutics Alternative Investment Market AIM SLN ref cite web title Google Finance Stock Exchange listing for Silence Therapeutics url http www.google.co.uk finance?q LON SLN accessdate 2011 09 16 ref is a biotechnology company that develops Gene therapy gene therapeutic technology based on RNA interference RNAi . They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters based in Royal Institution The Royal Institution of Great Britain , Mayfair, London. Profile The targeting, delivery and on going structural modification of sequences are the three platforms for Silence Therapeutics s RNAi therapeutic development. These three platforms are Gene therapy Lipoplexes and polyplexes proprietary delivery using ... and scientific research development of siRNA structural features Silence Therapeutics develops ... Therapeutics AG. More recently in January 2010, Silence Therapeutics merged with Intradigm Corporation ... interference. ref cite web first Stockopedia url http www.stockopedia.co.uk share prices silence therapeutics LON SLN title Stockopedia Silence Therapeutics Company History accessdate 2011 09 16 publisher Stockopedia ref Partnerships Silence Therapeutics has multiple partnerships with other pharmaceutical ... Pharma Dainippon Sumitomo . ref cite web first Silence Therapeutics url http www.silence therapeutics.com content collaborations partnerships.htm title Silence Therapeutics Collaborative Partnerships accessdate 2011 09 26 publisher Silence Therapeutics ref References reflist External links http ... more details
Unreferenced date September 2008 Infobox Company company name Halozyme Therapeutics logo Image Halozyme Therapeutics Logo.gif company type Public company Public nasdaq HALO company slogan foundation 1998 location San Diego, California , United States USA key people Jonathan E. Lim , President & CEO num employees 130 industry Biopharmaceutical products biologic medical product Biologic s revenue profit 3,799,521 United States dollar USD 2007 homepage http www.Halozyme.com www.halozyme.com Halozyme Therapeutics , based in San Diego, California , is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology , oncology , dermatology and drug delivery markets. http www.halozyme.com Category Companies in the NASDAQ Biotechnology Index Category Companies based in San Diego, California ... more details
Use mdy dates date September 2010 Infobox company name Acorda Therapeutics Inc. logo Image Acorda therapeutics inc logo.PNG 220px Acorda Therapeutics caption type Public company Public traded as nasdaq ACOR FWB CDG genre fate predecessor successor foundation Start date 1995 ref name Acorda FAQ http phx.corporate ir.net phoenix.zhtml?c 194451&p irol faq Acorda FAQ ref founder Ron Cohen defunct location city Hawthorne, New York location country United States location locations area served key people Ron Cohen br Andrew R. Blight industry Health care br Biotechnology products Tizanidine Zanaflex br 4 Aminopyridine Ampyra production services revenue profit United States Dollar US 54.7 Million small FY 2009 small ref name 09IncomeStatement wikinvest stock Acorda Therapeutics ACOR Data Income Statement Acorda Therapeutics ACOR annual SEC income statement filing via Wikinvest ref operating income loss United States Dollar US 79.5 Million small FY 2009 small ref name 09IncomeStatement net income loss United States Dollar US 83.9 Million small FY 2009 small ref name 09IncomeStatement assets increase United States dollar US 319 Million small FY 2009 small ref name 09BalanceSheet wikinvest stock Acorda Therapeutics ACOR Data Balance Sheet Acorda Therapeutics ACOR annual SEC balance sheet filing via Wikinvest ref equity decrease United States dollar US 137 Million small FY 2009 small ref name ... www.acorda.com Acorda.com footnotes intl Acorda Therapeutics nasdaq ACOR , FWB CDG is a biotechnology company based in Hawthorne, New York . Acorda Therapeutics develops drugs to improve therapies that improve ... of the board of directors of Acorda Therapeutics are ref http phx.corporate ir.net phoenix.zhtml ... Official website http www.acorda.com http topics.nytimes.com top news business companies acorda therapeutics inc index.html Acorda Therapeutics Inc. The New York Times http www.hoovers.com global cobrands nasdaq factsheet.xhtml?ID 121830 Acorda Therapeutics Inc. Hoover s Pharmaceutical companies of the United ... more details
Unreferenced date May 2010 ARYx Therapeutics, Inc. nasdaq ARYX is an United States American bio pharmaceutical company, headquartered in Fremont, California , focused on developing a portfolio of internally discovered product candidates. The company uses its RetroMetabolic Drug Design technology to design molecules that retain the efficacy of original and well established drugs but which are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these original compounds. References Reflist External links http www.aryx.com Official website Pharmaceutical companies of the United States DEFAULTSORT Aryx Therapeutics, Inc. Category Pharmaceutical companies of the United States ... more details
Orphan date December 2011 Infobox company company name Edge Therapeutics company logo File Edge therapeutics logo.jpg location Providence, NJ , U.S. foundation 2009 key people Brian Leuthner small President & CEO small R Loch Macdonald small Chief Scientific Officer small Carl Soranno small VP , Corporate Development small Priya Jambhekar small VP , Regulatory & Quality business Quality small Som Ming Leung small Associate Director, Corporate Operations small industry Pharmaceutical industry homepage http www.edgetherapeutics.com Edge Therapeutics, Inc. is a hospital focused biopharmaceutical company established in 2009 and headquartered in Providence, NJ. NimoGel, Edge s lead product, is being developed to prevent secondary stroke s after subarachnoid hemorrhage SAH , which is caused by bleeding into the fluid around the brain. NimoGel combines a generic calcium channel blocker nimodipine , formulated in a biodegradable ref cite news last Kling first Jim title Edge Therapeutics Inc. url http sis.windhover.com buy abstract.php?id 2011900062&utm source toc&utm medium website accessdate 7 July 2011 newspaper Start Ups Across Healthcare date 1 March 2011 ref polymer carrier composed of FDA approved materials. NimoGel is designed to be administered locally to the brain after surgery, directly to the site of the ruptured brain aneurysm or traumatic brain injury TBI to prevent vasospasm , a major contributor to post operative stroke . ref cite news last Bouley first Jeffrey title True relief with sustained release for largely unmet neurological problem url http www.drugdiscoverynews.com ... 2010 ref ref cite news last McCallister first Erin title Edge Therapeutics Finding Nimo url http ... cite news title Edge Therapeutics Appoints Scientific Advisory Board Members and Business Advisors url http www.marketwire.com press release edge therapeutics appoints scientific advisory board members ... Authority . ref cite web title Edge Therapeutics, Inc. url http www.onemedplace.com database ... more details
nofootnotes date May 2011 Image Opexa Therapeutics logo.jpg right Opexa Therapeutics corporate logo Opexa Therapeutics nasdaq OPXA , formerly known as PharmaFrontiers , is a biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis , congestive heart failure , and diabetes . The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T cell vaccination technologies. Key products and research include Tovaxin A T cell therapeutic vaccine for multiple sclerosis Heart Cardiac stem cell therapy Diabetes mellitus Diabetes stem cell therapy Location Opexa Therapeutics is located in The Woodlands, Texas The Woodlands , Texas convert 30 mi km north of Houston , Texas . The company has a convert 10200 sqft m2 abbr on facility on convert 3 acre m2 in The Woodlands, Texas The Woodlands . This location provides space for pipeline development through R & D a specialized Flow cytometry and Microscopy lab support of clinical trials with Good manufacturing practice GMP manufacturing Suites Quality Systems management with Quality Control Laboratory, Regulatory Affairs, Quality Assurance as well as administrative support space. On, November 08, 2011 Tovaxin was given a fast track designation by the FDA. This means Tovaxin will, with almost 100 certainty, be approved by the FDA and will reach the market faster than previously expected. The huge benefit of this drug is that it is created uniquely for each patient, which gives each patient with MS a treatment designed specifically for that individual so it will be more effective. Also, it is injected once every 3 5 months , most other treatments use a pill that must be taken everyday. This allows the patient to be worry free from having to remember to take a pill everyday and making monthly trips to the pharmacist. External links http www.opexatherapeutics.com Opexa Therapeutics webpage http news.bbc.co.uk 1 hi health 4787430.stm BBC Article 3 8 ... more details
Infobox Company name TauRx Therapeutics logo type Public company Public genre foundation Singapore 2002 founder Professor Claude Wischik br Dr K. M. Seng location city location country location Singapore locations area served key people Professor Claude Wischik, small Executive Chairman small br Dr Shay Way Seng, small Managing Director small br John Harry, small Lead Pharmaceutical Strategist small industry Medication Pharmaceuticals products services market cap revenue operating income net income assets equity owner num employees parent divisions subsid homepage http www.taurx.com TauRx Therapeutics footnotes intl yes TauRx Therapeutics Ltd is a startup pharmaceutical company that is based in Singapore . ref cite web last Marchione first Marilynn title Experimental Alzheimer s drug shows early promise publisher Associated Press date 2008 07 30 url http ap.google.com article ALeqM5jK3o2IH 4QHTz4i5e9OlzzFCA2pgD927P6QO0 accessdate 2008 07 31 ref The company was founded in 2002 by the late gynecologist , surgeon and venture capitalist K. M. Seng and the research biologist Claude Wischik who is currently its CEO. In 1988 Wischik and coworkers discovered that abnormal fibres of tau protein form inside nerve cells in patients with Alzheimer disease , and that their aggregation correlatates to the development of dementia . The company has focused on the development of drugs that dissolve tau fibres in an attempt to manage patients with Alzheimer. Rember is an investigational drug for this purpose by TauRx Therapeutics. ref cite web last Wilkinson first Emma title Alzheimer s drug halts decline publisher BBC date 2006 07 29 url http news.bbc.co.uk 2 hi health 7525115.stm BBC news accessdate 2008 07 29 ref References references External links http www.taurx.com Official site Category Pharmaceutical companies Category Companies of Singapore ... more details
infobox company name Opsona Therapeutics logo Image Opsona Therapeutics logo 200x73.jpg 200px Opsona Therapeutics is a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune Inflammation inflammatory conditions, cancer s and infectious disease s. ref http www.irishtimes.com newspaper innovation 2009 0302 1224241917142.html Article in the Irish Times ref ref http www.sbpost.ie post pages p story.aspx qqqt People In Business qqqm nav qqqid 39708 qqqx 1.asp Sunday Business Post article ref ref http investing.businessweek.com research stocks private snapshot.asp?privcapId 20741516 BusinessWeek company profile ref Based in Ireland , Opsona is a spin out from Trinity College Dublin TCD ref http www.irishtimes.com newspaper finance 2008 0623 1214047001272.html Article in the Irish Times ref . Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field ref http www.topuniversities.com worlduniversityrankings results 2007 overall rankings top 100 universities Times Higher Educational Supplement QS World University Rankings 2007 ref . Opsona s research is primarily focused on the role of Toll like receptors TLRs and TLR signalling in human innate immunity . The company was founded in 2004 by three immunologists Professor Luke O Neill ref http www.irishexaminer.ie ireland trinity team makes vaccine discovery 90894.html Article in the Irish Examiner ref Professor Kingston Mills ref http www.tcd.ie Biochemistry research k mills.php Article on the Trinity College Dublin website ref Professor Dermot Kelleher ref http www.tcd.ie Communications news news.php?headerID 1108&vs date 2009 2 1 Article on the Trinity College Dublin website ref Opsona s main investors are international and life science focused Inventages Venture Capital Bahamas ref http www.fiercebiotech.com press releases opsona therapeutics closes eur18m funding 0 Article on Fierce Biotech ref Seroba Bioventures ... more details
Sirna Therapeutics, Inc. was a San Francisco , California based biotechnology company that explores the use of RNA interference in human disease therapy. Sirna s development pipeline includes several small interfering RNA siRNA drug s, thought to stably gene silencing silence the gene expression expression of specific disease related genes. Sirna s clinical trial of an siRNA based treatment for age related macular degeneration is the first such trial for an siRNA drug. ref name Sirna cite web url http www.sirna.com wt page ocular title Ocular Therapeutic Pipeline accessdate 2007 02 12 archiveurl http web.archive.org web 20070127073635 http www.sirna.com wt page ocular Bot retrieved archive archivedate 2007 01 27 ref ref name Sah Sah D 2006 . Therapeutic potential of RNA interference for neurological disorders . Life Sci 79 19 1773 80. DOI 10.1016 j.lfs.2006.06.011 PMID 16815477 ref Sirna Therapeutics was acquired by Merck & Co. in 2006 in a cash transaction deal worth 1.1 billion. ref name Merck http phx.corporate ir.net phoenix.zhtml?c 141787&p irol newsArticle&id 945592&highlight Merck & Co., Inc. Announces Completion of Acquisition of Sirna Therapeutics, Inc. Merck & Co . Retrieved on March 3, 2012. ref Headquarters and laboratory Sirna maintained its laboratory on the northeastern edge of Boulder, Colorado . ref name DirLab http web.archive.org web 20060311061801 http www.sirna.com sirnacontact directions.html Directions . Sirna Therapeutics. March 11, 2006. Retrieved on March 3, 2012. ref Originally the corporate headquarters were also located in Boulder. Sirna, at one point, launched a search for a new headquarters complex. It originally considered multiple cities, including ... BUGMTBKQNM1.DTL Another biotech arrival Sirna Therapeutics moving to S.F. s Mission Bay area . San Francisco ... web 20060311061724 http www.sirna.com sirnacontact hq.html Boulder Campus . Sirna Therapeutics ... Francisco Bay Area Colorado Companies http web.archive.org http www.sirna.com Sirna Therapeutics ... more details
Infobox Company name Proteon Therapeutics company logo Image Proteon therapeutics logo.JPG 249px Proteon Therapeutics type Privately held company Private foundation industry Pharmaceuticals homepage http www.proteontherapeutics.com www.proteontherapeutics.com Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts Waltham , Massachusetts and Kansas City, Missouri Kansas City , Missouri . It is developing PRT 201, a drug to improve blood flow following vascular surgery procedures, and, more broadly, is interested in vascular access for hemodialysis and peripheral arterial disease PAD . On September 10, 2008, Proteon announced that the Food and Drug Administration had granted fast track status to PRT 201. Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University . Major investors in the company include MPM Capital , Rockhill Partners , TVM Capital , Skyline Ventures , Prism VentureWorks , Vectis Life Sciences and Intersouth Partners . They have invested over 72 million in the company. ref cite news first Rob last Roberts authorlink coauthors title Proteon secures 12M in financing url http www.bizjournals.com kansascity stories 2007 04 02 daily30.html work Kansas City Business Journal publisher date April 5, 2007 accessdate 2008 07 27 ref On March 5, 2009, the company announced that it had raised 32 million from its existing investors plus MPM Capital and Vectis Life Sciences. Proteon also announced that it had entered into an option agreement to be acquired by Novartis for up to 550 million. ref cite news url http www.boston.com business ticker 2009 03 proteon raises.html work The Boston Globe title Proteon raises 38m, signs option deal with Novartis date March 5, 2009 ref References Reflist cite news first Rob last Roberts authorlink coauthors title Proteon secures 12M in financing ... Proteon Therapeutics, Inc. Pharmaceutical companies of the United States Category Pharmaceutical ... more details
Infobox Company company name IL Therapeutics Inc. company type foundation location 105E 111 Research Drive, Saskatoon, Saskatchewan Saskatoon , Saskatchewan SK , Canada key people industry Biotechnology num employees products homepage IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP Western Life Sciences and in 2006 its shares were purchased by Pacgen Biopharmaceuticals Corporation Pacgen ref name pac Citation last Pacgen Biopharmaceuticals Corporation first author link last2 first2 author2 link title Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc. date year url http www.pacgenbiopharm.com investor pdfs news release20060412.pdf accessdate Sept 9, 2007 ref History Saskatchewan Research Council operates a bio processing laboratory which facilitated biomedical research. IL Therapeutics was developed from research first begun at the Western College of Veterinary Medicine Pharmaceuticals Currently IL Therapeutics is working on a drug candidate, IL 8 3 73 K11R G31P PAC G31P for relief of Acute Respiratory Distress Syndrome ARDS ref name pac3 Citation last Pacgen Biopharmaceuticals Corporation first author link last2 first2 author2 link title Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc. date year url http www.pacgenbiopharm.com investor releases 20060412.html accessdate Sept 9, 2007 ref The Saskatchewan Research council, SRC also assisted with the funding of this project through the Agriculture Development Fund SRC Industry Venture Fund. ref name src Citation last Saskatchewan Research Council 2005 2006 Annual Report first author link last2 first2 author2 link title Sustainable Science Solutions date year url http www.src.sk.ca store account download file.cfm?productID 3483&freeDownloadID 538 accessdate Sept 9, 2007 ref The successful progression of G31PRecently the University of Saskatchewan Industry Liaison Office ILO decided to commercialize a commercialize this new drug treatment. ref name UofS Citation last U of S News ... more details
coord 40.550722 74.4230711 type landmark region US NJ display title PTC Therapeutics is a pharmaceutical company. It is headquartered in South Plainfield , New Jersey . They are the company responsible for the development of PTC124 . ref name pmid17096300 cite journal author Hamed SA title Drug evaluation PTC 124 a potential treatment of cystic fibrosis and Duchenne muscular dystrophy journal IDrugs the investigational drugs journal volume 9 issue 11 pages 783 9 year 2006 pmid 17096300 doi ref As of September 2009, PTC has entered into an agreement with Hoffmann La Roche Roche for the development of orally bioavailable small molecules for central nervous system disease targets. Roche said use of PTC s GEMS technology for the identification of small molecules will enable Roche to address important disease mechanisms that were intractable with conventional approaches. ref http www.firstwordplus.com Fws.do?articleid A2B13ACB78294EB0A27EE127D8339BF3 ref References references Further reading ref name Schneider2009 Cite journal title Firm Aims to Regulate RNA in Rare Diseases url http www.genengnews.com articles chitem.aspx?aid 2869 year 2009 author Schneider, Ilene journal Genetic Engineering & Biotechnology News pages 14 volume 29 issue 8 accessdate 2009 04 25 postscript None ref External links http www.ptcbio.com DEFAULTSORT PTC Therapeutics Category Biotechnology Category Clinical research Category Pharmaceutical industry Category Pharmacology Category Pharmacy Category Companies based in New Jersey pharmacology stub ... more details
Insert Therapeutics , Inc., now Calando Pharmaceuticals, Inc., is a medical research company that uses nanobiotechnology specializing in therapeutic agents that are conjugation chemistry conjugate d Disambiguation needed date March 2012 , to facilitate and enhance drug delivery . The small company was founded in 2000, is located in Pasadena, California , and majority owned by Arrowhead Research Corporation . The conjugates consist of a cyclodextrin containing polymer Cyclosert that acts as a drug delivery system, and a linked medication, such as a chemotherapeutic drug of already proven efficacy. ref name IT 101 http clinicaltrials.gov ct show NCT00333502?order 1 IT 101 trial ref The size of the polymer is designed to fit the specific target, as vessels in a neoplasm allow for leakage of different size of polymers, as in healthy tissue. The leaked conjugates are concentrated in the target area. As a result chemotherapeutic activity is locally enhanced, while general side effects are decreased. ref name IT 101 At least one of their conjugates, IT 101 , has been investigated in a clinical trial at City of Hope National Medical Center . ref name IT 101 References Reflist External links http www.calandopharma.com Calando Pharmaceuticals, Inc. was Insert Therapeutics, Inc. http www.ceruleanrx.com Cerulean Pharma, Inc. IT 101 licensee Category Biotechnology ar ... more details
Infobox company company name Osseon Therapeutics, Inc. company logo File Osseon logo.jpg location Santa Rosa, California, USA key people John Stalcup , CEO industry Medical technology products Medical devices homepage http www.osseon.com osseon.com Osseon Therapeutics, Inc. , designs medical devices to treat degenerative bone and joint disease. Based in Santa Rosa, California , the company develops and manufactures devices to treat compression fractures of the thoracic and lumbar vertebral spine. References Reflist http www.beckersorthopedicandspine.com orthopedic spine device implant news item 1544 42 Orthopedic and Spine Device Companies to Know http www.pressdemocrat.com article 20100408 ARTICLES 100409536 1052 OBITS?p all Foreign Sales Boost Santa Rosa Medical Device Maker http www.pressdemocrat.com article 20101014 BUSINESS 101019732 Osseon Signs Deal with Johnson & Johnson http www.mddionline.com article 50 companies watch 0 50 Companies to Watch http www.breitbart.com article.php?id xprnw.20100506.NE99998 DFine, DePuy, and Osseon Making Headway in the US Vertebral Compression Fracture Treatment Market External links http www.emedicinehealth.com vertebral compression fracture article em.htm Vertebral Compression Fracture information on eMedicineHealth http www.webmd.com osteoporosis vertebral compression fracture California Corporations Category Medical Equipment Manufacturers Category Surgical Instruments Category Interventional Radiology Category Medical Device Manufacturers Category Health care companies of the United States ... more details
Orphan date February 2009 Unreferenced date February 2007 Pharmacy and Therapeutics is a committee at a hospital or an insurance plan that meets to decide which drugs will appear on that entity s drug formulary. The committee usually consists of both physicians and pharmacists. They must weigh the costs and benefits of each drug and decide which ones provide the most efficacy per dollar. Most generic drugs are available on formularies, except in cases where that class of drugs are no longer considered safe and efficacious. For instance most formularies will not cover barbiturates since their therapeutic index is low compared to benzodiazepines . Barbiturates have a danger of overdosing that occurs at a smaller milligram range than the benzodiazepines. Category Hospitals Pharma stub ... more details
Infobox Company company name Prime Therapeutics company logo File Prime therapeutics llc.jpg 250px div style height 0.5em clear both div company type Limited Liability Corporation foundation 1998, created by a merger location Eagan, Minnesota key people Eric Elliott, CEO br Don Amorosi, COO br David Lassen, PharmD, Chief Clinical Officer br Charles Roehrick, CFO br Duane Barnes, SVP Consumer Delivery br Jacqueline Chase, SVP Human Resources br John Mielke, CBO & CTO br Cameron Olig, SVP, Client Services br Sara Ratner, Chief Compliance Office br Peter Wickersham, SVP, Cost of Care br Matt Yordy, SVP, Business Development industry Pharmacy Benefit Management, Mail Order Pharmacy num employees 2,100 2011 parent Blue Cross and Blue Shield of Alabama , Blue Cross and Blue Shield of Florida , Blue Cross and Blue Shield of Illinois , Blue Cross and Blue Shield of Kansas , Blue Cross and Blue Shield of Minnesota , Blue Cross and Blue Shield of Montana , Blue Cross and Blue Shield of Nebraska , Blue Cross and Blue Shield of New Mexico , Blue Cross and Blue Shield of North Carolina eff. 4 1 12 , Blue Cross Blue Shield of North Dakota , Blue Cross and Blue Shield of Oklahoma , Blue Cross and Blue ... URL http www.primetherapeutics.com TOC Prime Therapeutics LLC is a Pharmacy Benefit Manager PBM ..., New Mexico, North Carolina, North Dakota, Oklahoma, Texas and Wyoming. Prime Therapeutics operates ..., IL , Jacksonville, Florida , Hoover, Alabama , Pittsburgh, PA and Washington, D.C. Prime Therapeutics ... , Express Scripts Incorporated , and Catalyst Rx. Prime Therapeutics covers nearly 20 million lives ... and service bureau, and is renamed Prime Therapeutics, Inc. Prime is a privately held corporation ... Cross and Blue Shield of Texas purchases equity ownership 2004 Prime Therapeutics, LLC is formed ... Prime Therapeutics ref Cite news title Our Story url http www.primetherapeutics.com our story.html ... Electronic Refill Requests REFREQ REFRES Medication History Requests RXHREQ RXHRES Prime Therapeutics ... more details
Infobox company company name Regulus Therapeutics Inc. company logo Deleted image removed Image RegulusTherapeuticsInc.gif 210px company type Private company foundation September 2007 by Alnylam Pharmaceuticals NASDAQ ALNY and Isis Pharmaceuticals NASDAQ ISIS location San Diego, California , USA key people Kleanthis G. Xanthopoulos, Ph.D. President and CEO br Garry E. Menzel, Ph.D. COO and EVP Finance br Neil W. Gibson, Ph.D. CSO br Hubert C. Chen, M.D. VP of Translational Medicine br Lars Karlsson, M.D., Ph.D. VP of Immunology and Fibrosis industry Biotechnology products microRNA therapeutics num employees 54 homepage http www.regulusrx.com www.regulusrx.com Regulus Therapeutics Inc. or Regulus is a biopharmaceutical company focused on the development of microRNA based drugs targeting fibrosis, metabolism and cardiovascular diseases, cancer, HCV and immune related diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. ref name drugdiscoverynews cite web url http www.drugdiscoverynews.com index.php?newsarticle 5030 title Omics & Systems Biology, Surf s Up for microRNAs publisher Drug Discovery News author Hutton, David, date June 2011 ref microRNA Explained MicroRNAs are small naturally occurring RNA molecules, typically 20 to 25 nucleotides ... & Biotechnology News author Liszewski, Kathy date May 15, 2011 ref anti miR Therapeutics Anti miR therapeutics inhibit specific microRNA targets. Animal models showed that modulating microRNAs ... pharmtech Drug Delivery Perspectives in MicroRNA Therapeutics ArticleStandard Article detail 718858 title Perpectives in MictoRNA Therapeutics, publisher Pharmaceutical Technology author Steffy, Kevin ... and commercialization of novel microRNA targeted therapeutics to treat inflammatory diseases such as rheumatoid ... and commercialize microRNA therapeutics targeting microRNA 122 miR 122 for the treatment of hepatitis ... Therapeutics official website cite journal pages 2921 31 doi 10.1172 JCI57275 title Antagonism ... more details
Cynapsus Therapeutics Inc. TSXV CTH is a specialty clinical development pharmaceutical company targeting diseases of the brain. Based in Toronto , Canada . Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. ref http www.marketwire.com press release Cannasat Changes Name to Cynapsus Therapeutics TSX VENTURE CTH 1148145.htm ref Company Overview Cynapsus is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cynapsus has a lower risk Parkinson s drug candidate, which is a reformulation of an approved drug that can address a moderate to severe patient population. Cynapsus also has a proprietary formulation technology for cannabinoid drug candidates, which may be used to treat neuropathic pain associated with multiple sclerosis and cancer, as well as for nausea vomiting and appetite stimulation. Cynapsus s strategy is to grow its portfolio of drug candidates through in licensing and acquisitions, and to advance projects to Phase 2 proof of concept clinical studies. Once the drug candidates are sufficiently derisked, Cynapsus intends to out license the programs to the appropriate Pharma marketing partners for a combination of upfront, milestone, and royalty payments. Products RELIVAR Relivar, a buccal tablet for symptomatic management of neuropathic pain, contains the active ingredient, dronabinol or THC . THC has been clinically has been shown to be efficacious for neuropathic pain in numerous clinical trials which have been published in reputable peer reviewed journals. Undesired psychoactivity associated with higher doses of the oral formulation has limited its utility for this indication. Relivar aims to deliver the drug in the oral cavity by incorporating it into a tablet that adheres to the gum and releases the drug in the mouth. The benefits are two fold 1 promoting direct absorption through the gums, Relivar can achieve increased bioavailability and reduce the dose required for efficacy ... more details
Antibe Therapeutics is a Toronto based pharmaceutical research and development company developing inflammation reducing drugs. ref http www.antibe therapeutics.com ref The conceived mechanism of action is to deliver a gaseous mediator , specifically hydrogen sulfide to sites of inflammation or injury within the human body. Hydrogen sulfide enhances the resolution of injury and repair of damage. Antibe was founded by John L. Wallace , co founder of NicOx , the company that was the first to commercialize gaseous mediator technology. Antibe s board of directors includes Louis Ignarro , awarded the 1998 Nobel Prize in Physiology or Medicine for the basic research that underpins gaseous mediator technology, and Dr. Daniel K. Podolsky, Presient of the University of Texas Southwestern . Antibe s products have not yet been approved by the Food and Drug Administration . The lead drug, ATB 346, is a hydrogen sulfide releasing derivative of naproxen, a commonly used non steroidal anti inflammatory drug . Unlike naproxen, ATB 346 does not induce damage in the gastrointestinal tract. Canada company stub References reflist External links http www.nicox.com Official website of NicOx http www.nitricoxideonline.net Nitric Oxide Knowledge Center Website of NicOx Category Pharmaceutical companies of France Category SBF 120 de Nicox fr Nicox http www.ncbi.nlm.nih.gov pmc articles PMC1363746 ... more details
Infobox company name Pluristem Therapeutics Inc. logo caption type Public company Public traded as Nasdaq PSTI br TASE PSTI br FWB PJTA fate successor foundation Start date 2001 05 11 founder Shai Meretzki defunct End date YYYY MM DD location city Haifa location country Israel location locations area served key people Zami Aberman small Chairman and CEO, 2005 small industry Biotechnology products services revenue Israeli new shekel 0 small 2010 small operating income 30.39 million small 2010 small net income assets 27.97 million small 2010 small equity owner num employees parent divisions subsid homepage Url www.pluristem.com footnotes ref cite web title TASE Site Profile url http www.tase.co.il TASEEng General Company companyDetails.htm?subDataType 0&companyId 001569&ShareId 01121730 SummaryLink publisher Tel Aviv Stock Exchange accessdate 22 September 2011 year 2011 ref intl Pluristem Therapeutics is an Israel i company engaged in the development of human placenta l adherent stromal cell s for commercial use in disease treatment. ref cite web title Pluristem Therapeutics Inc PSTI NASDAQ CM url http investing.businessweek.com research stocks snapshot snapshot article.asp?ticker PSTI US work Bloomberg Businessweek accessdate 22 September 2011 quote The company engages in the development of a pipeline of products, which are derived from human placenta, a non controversial, non embryonic, and adult stromal cell source. ref According to the company s website, it extracts adult stem cells exclusively from postnatal placentas. ref cite web title Pluristem Who we are url http www.pluristem.com index.php?option com content&view article&id 6&Itemid 19 publisher Pluristem accessdate 22 September 2011 quote Pluristem has made the strategic decision to work only with adult stem cells, purified from the placenta after birth and, therefore, not subject to ethical or religious controversy ... to Pluristem Therapeutics Inc. ref name marketwatch Pluristem s shares are traded on the NASDAQ ... more details
Orphan date February 2009 Ortek Therapeutics, Inc. is a private pharmaceutical company based in Roslyn Heights, New York which specializes in researching and commercializing oral care products. It was founded in 1998. Their most notable technology is the company s patented arginine bicarbonate calcium carbonate complex, which is incorporated in their sugarless BasicMints product line. Arginine, a common amino acid found in saliva, is broken down by oral plaque bacteria to acid neutralizing alkali. This results in a neutral or elevated oral plaque pH, which creates an optimal environment for remineralization of the teeth. The calcium component is available for enhanced remineralization and the bicarbonate component also aids in buffering the teeth from acid attacks. This technology, which is based on over 40 years of research in saliva chemistry, was licensed to the company by The Research Foundation of the State University of New York after being developed by Department of Oral Biology and Pathology at Stony Brook University. A 2008 clinical trial published in the Journal of Clinical Dentistry found that BasicMints were highly effective in preventing caries in Venezuelan children, as those consuming the mints had 62 less cavities than the placebo group. ref http www.dentistry.co.uk news news detail.php?id 1160 Experimental chewy mint beats tooth decay ref Ortek developed and commercialized two dental pastes for sensitive teeth and were based on the arginine bicarbonate calcium carbonate technology. These products, DenClude and ProClude were sold to Colgate Palmolive in 2008. ProClude, is now called Colgate Sensitive Pro Relief Desensitizing Paste. BasicMints have not been commercialized, but the company is planning a launch in the near future. The company is also in late stage development of an electronic early cavity detector, called the Ortek ECD. See also Dentistry Xylitol References reflist External links http www.ortekinc.com Company homepage Category Dental companies ... more details
Repros Therapeutics Inc. NASDAQ RPRX , is a United States US based development stage biopharmaceutical company headquartered in The Woodlands, Texas . Founded in 1987 as Zonagen, it is focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health. Joseph S. Podolski ref name Joseph S. Podolski Profile http people.forbes.com profile joseph s podolski 67949 Joseph S. Podolski Profile , Forbes.com ref is the CEO of this company. History The company was organized on August 28, 1987 as Zonagen, to try to develop birth control methods based on modification of the zona pellucida a part of the oocyte . The company bought the rights to the research of Bonnie Dunbar, researcher and professor at the Baylor College of Medicine , and attempted to create a contraceptive vaccine. Zonagen, Inc. was formed in 1987 by Dunbar, Baylor and a group of investors that included Ross Perot and Lloyd Bentsen III, son of a former treasury secretary. The company hoped to market Dunbar s invention as a nonsurgical method of sterilizing dogs and cats. In the meantime, Zonagen would help Dunbar continue the pursuit of her life s work the world s first contraceptive vaccine for humans. Her research, which had been progressing well, ground to a complete halt according to Brian Wallstin of the Houston Press newspaper in his article Biological Disaster. ref Brian Wallstin, http www.houstonpress.com 1998 08 20 news biological disaster Biological Disaster , Houston Press Aug 20 1998 ref The company, went public in 1993 with claims that a contraceptive vaccine was imminent. Bonnie Dunbar ended relations with the company and sued them. Zonagen would not develop any commercial product from research relating to the zona pellucida despite naming itself after it. Its next project was to create an adjuvant. These products modify the effects of the active ingredient ... its name to Repros Therapeutics, started to develop other pharmaceutical products for the reproductive ... more details
Encyclopedia
top
